Product Overview

Bone marrow is obtained from normal donors by bilateral aspirates of the posterior iliac crest. Donors are screened for general health, normal blood counts and infectious diseases prior to collection. 

CD34+ selected cells are a highly purified population of progenitor cells and allow for greater cell expansion and differentiation down multiple pathways. CD34+ and CD133+ progenitors can differentiate into a number of precursors and differentiated cell types. 

Hematopoietic progenitors express high levels of the cell surface glycoprotein CD34. As these cells mature and differentiate, the levels of CD34 decrease. CD34+ cells are capable of initiating long-term hematopoiesis both in vitro and in vivo and are therefore utilized in the therapeutic re-constitution of bone marrow. 

Lonza offers CD34+ progenitors isolated from mononuclear cells using positive immunomagnetic selection. CD34+ progenitors are available cryopreserved in quantities starting from ≥100,000 cells/order from single or multiple donors. Purity is ≥95% for bone marrow derived cells and ≥90% for cord blood derived cells.

Recommended Media and Reagents

• HPGM^TM Hematopoietic Growth Medium - 500 ml (Lonza Catalog No. PT-3926) 

Cytokines for Proliferation

• Recombinant Human TPO (ThermoFisher Catalog No. PHC9511 or similar)
• Recombinant Human SCF (ThermoFisher Catalog No. PHC2111 or similar)
• Recombinant Human Flt-3 Ligand (SigmaAldrich Catalog No. SRP3044 or similar)